Pros and cons of different therapeutic antibody formats for recombinant antivenom development

Andreas H. Laustsen*, José María Gutiérrez, Cecilie Knudsen, Kristoffer H. Johansen, Erick Bermúdez-Méndez, Felipe A. Cerni, Jonas A. Jürgensen, Line Ledsgaard Jensen, Andrea Martos Esteban, Mia Øhlenschlæger, Urska Pus, Mikael R. Andersen, Bruno Lomonte, Mikael Engmark, Manuela B. Pucca

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

1494 Downloads (Pure)


Antibody technologies are being increasingly applied in the field of toxinology. Fuelled by the many advances in immunology, synthetic biology, and antibody research, different approaches and antibody formats are being investigated for the ability to neutralize animal toxins. These different molecular formats each have their own therapeutic characteristics. In this review, we provide an overview of the advances made in the development of toxin-targeting antibodies, and discuss the benefits and drawbacks of different antibody formats in relation to their ability to neutralize toxins, pharmacokinetic features, propensity to cause adverse reactions, formulation, and expression for research and development (R&D) purposes and large-scale manufacturing. A research trend seems to be emerging towards the use of human antibody formats as well as camelid heavy-domain antibody fragments due to their compatibility with the human immune system, beneficial therapeutic properties, and the ability to manufacture these molecules cost-effectively.


Original languageEnglish
Pages (from-to)151-175
Publication statusPublished - 2018


  • Antivenom
  • Venom
  • Recombinant antivenom
  • Antibodies
  • Snakebite
  • Scorpion sting
  • Spider bite
  • Animal envenoming
  • Pharmacokinetics
  • Pharmacodynamics
  • Immunogenicity
  • Venom neutralization
  • Antibody expression
  • Antivenom design
  • Adverse reactions
  • Neglected tropical diseases
  • Biotechnology


Dive into the research topics of 'Pros and cons of different therapeutic antibody formats for recombinant antivenom development'. Together they form a unique fingerprint.

Cite this